School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA.
J Infect Dis. 2012 Nov 15;206(10):1604-11. doi: 10.1093/infdis/jis552. Epub 2012 Sep 10.
Staphylococcus aureus bacteremia (SaB) carries considerable morbidity and mortality. We examined the predictive value of serum concentrations of interleukin (IL)-10, proinflammatory cytokines, and terminal complement on patient survival and SaB duration.
Clinical information on consecutive patients with SaB at a tertiary medical center were collected prospectively. Patient serum samples obtained at the day of clinical presentation were assayed for tumor necrosis factor-α, IL-1β, IL-10, and complement membrane attack complex C5b-9 concentrations using enzyme-linked immunoassay. Logistic regression identified predictors of mortality and duration of bacteremia.
In 59 patients with SaB, 14% died and 17% had prolonged bacteremia (>4 days). Elevated IL-10 serum concentrations (>7.8 pg/mL) identified all 8 patients who died, whereas there were no deaths in patients with normal IL-10 (P = .016). The lack of an IL-1β response (≤0.45 pg/mL) defined all patients with SaB >4 days. In multivariate analysis, patient age (odds ratio [OR], 1.16; P = .022), duration of bacteremia (OR, 1.16; P = .031), and serum IL-10 (OR, 1.05; P = .014) were identified as independent predictors of patient mortality.
SaB mortality was confined strictly to patients with elevated IL-10 concentrations. We recommend that future clinical trials of SaB stratify patients according to IL-10 and IL-1β serum concentrations in order to better evaluate the impact of therapeutic interventions on patient outcome.
金黄色葡萄球菌菌血症(SaB)具有相当高的发病率和死亡率。我们研究了白细胞介素(IL)-10、促炎细胞因子和末端补体在患者生存和 SaB 持续时间方面的预测价值。
我们前瞻性地收集了一家三级医疗中心连续的 SaB 患者的临床信息。在临床发病当天采集患者血清样本,采用酶联免疫吸附法检测肿瘤坏死因子-α、IL-1β、IL-10 和补体膜攻击复合物 C5b-9 浓度。逻辑回归确定了死亡率和菌血症持续时间的预测因素。
在 59 例 SaB 患者中,14%的患者死亡,17%的患者菌血症持续时间延长(>4 天)。血清 IL-10 浓度升高(>7.8 pg/mL)可识别所有 8 例死亡患者,而正常 IL-10 的患者无一例死亡(P =.016)。缺乏 IL-1β 反应(≤0.45 pg/mL)可定义所有 SaB >4 天的患者。在多变量分析中,患者年龄(比值比[OR],1.16;P =.022)、菌血症持续时间(OR,1.16;P =.031)和血清 IL-10(OR,1.05;P =.014)被确定为患者死亡的独立预测因素。
SaB 死亡率严格局限于 IL-10 浓度升高的患者。我们建议未来的 SaB 临床试验根据 IL-10 和 IL-1β 血清浓度对患者进行分层,以更好地评估治疗干预对患者结局的影响。